MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
CHICAGO–(BUSINESS WIRE)–MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that it will present the results of a study of the anticancer agent 6-thio-dG (THIO) in hepatocellular carcinoma (HCC) in vitro and in vivo models at the EORTC-NCI-AACR (ENA) Symposium on … [Read more…]
